Exploring causes for declining prostate cancer mortality rates in the United States

被引:12
作者
Colli, Janet L. [1 ,2 ]
Amling, Christopher L. [1 ]
机构
[1] Univ Alabama, Dept Urol, Birmingham, AL 35294 USA
[2] Birmingham VA Med Ctr, Birmingham, AL 35294 USA
关键词
Ecology; Prostate cancer; Risk factors; United States; Epidemiology;
D O I
10.1016/j.urolonc.2007.05.016
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives: Prostate cancer mortality rates in the U.S.A. increased in the late 1980s and declined from 1993 until 2003. The purpose of this study is to compare declining prostate cancer mortality rates among states with independent variables that may have an association to explore causes for the decline. Methods and materials: Annual rates of prostate cancer mortality for men over 50 were obtained from the National Vital Statistic System public use data file for states for individual years from 1993 to 2003. The annual rate of prostate cancer mortality decline for each state Was Calculated by the Joinpoint Regression Program (Statistical Research and Applications Branch of NCI). Annual rates of prostate cancer decline were cross-correlated to state levels of PSA screening, health insurance coverage, obesity, physical inactivity, diabetes, and high cholesterol for males front 45 to 64. Results: Declining prostate cancer mortality rates for white males correlated with high cholesterol levels (R = -0.42, P = 0.002) and PSA screening levels (R = -0.28. P = 0.05). Declining, prostate cancer mortality rates for black males correlated with health insurance coverage (R = -0.43. P = 0.03). Conclusions: Declining prostate cancer mortality rates are weakly associated with increased PSA screening for White Males but there was no association for black males, possibly because blacks have less access to medical care. The strong inverse correlation between declining prostate cancer mortality rates and levels of white males with high cholesterol levels was unexpected but may be associated with the widespread use of cholesterol reducing medications (statins), which are hypothesized to reduce prostate cancer risk. (c) 2008 Elsevier Inc. All rights reserved.
引用
收藏
页码:627 / 633
页数:7
相关论文
共 9 条
[1]   Statin use and the risk of breast and prostate cancer [J].
Coogan, PF ;
Rosenberg, L ;
Palmer, JR ;
Strom, BL ;
Zauber, AG ;
Shapiro, S .
EPIDEMIOLOGY, 2002, 13 (03) :262-267
[2]   Large-scale randomized prostate cancer screening trials:: Program performances in the European randomized screening for prostate cancer trial and the prostate, lung, colorectal and ovary cancer trial [J].
de Koning, HJ ;
Auvinen, A ;
Sanchez, AB ;
da Silva, FC ;
Ciatto, S ;
Denis, L ;
Gohagan, JK ;
Hakama, M ;
Hugosson, J ;
Kranse, R ;
Nelen, V ;
Prorok, PC ;
Schröder, FH .
INTERNATIONAL JOURNAL OF CANCER, 2002, 97 (02) :237-244
[3]   Cancer surveillance series: Interpreting trends in prostate cancer - Part II: Cause of death misclassification and the recent rise and fall in prostate cancer mortality [J].
Feuer, EJ ;
Merrill, RM ;
Hankey, BF .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1999, 91 (12) :1025-1032
[4]  
Moyad MA, 2004, UROL ONCOL-SEMIN ORI, V22, P466, DOI 10.1016/j.urolonc.2004.10.001
[5]  
*SEER PROGR, 2006, SEER STAT DAT MOR AL
[6]   Differential efficacy of 3-hydroxy-3-methylglutaryl CoA reductase inhibitors on the cell cycle of prostate cancer cells [J].
Sivaprasad, Umasundari ;
Abbas, Tarek ;
Dutta, Anindya .
MOLECULAR CANCER THERAPEUTICS, 2006, 5 (09) :2310-2316
[7]   Hypothesis: the antitumor activities of statins may be mediated by IL-18 [J].
Takahashi, Hideo Kohka ;
Weitz-Schmidt, Gabriele ;
Iwagaki, Hiromi ;
Yoshino, Tadashi ;
Tanaka, Noriaki ;
Nishibori, Masahiro .
JOURNAL OF LEUKOCYTE BIOLOGY, 2006, 80 (02) :215-216
[8]   The accuracy of primary care patients' self-reports of prostate-specific antigen testing [J].
Volk, RJ ;
Cass, AR .
AMERICAN JOURNAL OF PREVENTIVE MEDICINE, 2002, 22 (01) :56-58
[9]  
Zhuang LY, 2005, J CLIN INVEST, V115, P959